Evidence map›Paper›PMID 41932919›Full record

ArticleNature communications2026

Social reward outcompetes drug seeking dopaminergic ensembles to prevent relapse.

Wei Zheng, Xiaoxing Liu, Tangsheng Lu, Xinyou Lv, Xuefang Guan, Yifan Yu, Xue Li, Zhe Wang, Kai Yuan, Jeffrey W Grimm and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wei Zheng *Peking-Tsinghua Center for Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China.ORCID 0009-0008-4934-3203
Xiaoxing Liu *Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.ORCID 0000-0001-7592-0483
Tangsheng Lu *National Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Xinyou LvDepartment of Psychology, School of Humanities and Social Sciences, University of Science and Technology of China, Hefei, China.
Xuefang GuanHenan Academy of Innovation in Medical Science, Henan University, Kaifeng, China.ORCID 0009-0000-4644-9848
Yifan YuPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.ORCID 0000-0002-7455-6525
Xue LiNational Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Zhe WangInstitute of Brain Science and Brain-inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Kai YuanPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
Jeffrey W GrimmDepartment of Psychology and Program in Behavioral Neuroscience, Western Washington University, Bellingham, WA, USA.
Trevor W RobbinsBehavioural and Clinical Neuroscience Institute, Department of Psychology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0642-5977
Jie ShiNational Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China. shijie@bjmu.edu.cn.ORCID 0000-0001-6567-8160
Lin LuPeking-Tsinghua Center for Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China. linlu@bjmu.edu.cn.ORCID 0000-0003-0742-9072
Yan-Xue XueNational Institute on Drug Dependence, Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China. yanxuexue@bjmu.edu.cn.ORCID 0000-0003-2979-0045

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82071498
6 · The paper itself

Abstract

Drugs of abuse promote substance use disorder (SUD) by hijacking mesolimbic circuits that normally process natural rewards. Among these, social rewards exhibit therapeutic potential, but the underlying neural substrates remain unclear. Using a multimodal approach integrating in vivo single-neuron calcium imaging, optogenetic manipulation, and electrophysiology in male rats, we identified two distinct dopaminergic ensembles in the ventral tegmental area (VTA) that respectively encode social reward and drug seeking. Notably, these antagonistic ensembles exert reciprocal influence through competitive interactions that shape behavioral outcomes. Furthermore, circuit mapping revealed divergent connectivity patterns, with social reward-responsive dopaminergic ensembles receiving preferential input from the dorsal raphe nucleus (DRN). Activation of the DRN-VTA pathway recapitulates the protective effects of social reward against drug seeking. In this study, we uncovered a dynamic competition between functionally specialized dopaminergic ensembles through which social reward attenuates drug seeking, offering insights that may inform development of novel strategies for SUD treatment.

Indexed as

Dopaminergic NeuronsDrug-Seeking BehaviorRewardSocial BehaviorSubstance-Related DisordersVentral Tegmental AreaAnimalsDopamineDorsal Raphe NucleusMaleMesolimbic SystemOptogeneticsRatsRats, Sprague-DawleyDopamine

Identifiers

PMID41932919
PMCPMC13076667

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.